Search Results
Severe meibomian gland dysfunction linked to tear film instability in TED
Dry eye symptoms observed in treatment-naive thyroid eye disease (TED) predominantly manifest as evaporative dry eye disease, according to a...
Read MoreIRMPT for strabismus repair in TED results in durable relief of diplopia
Intraoperative relaxed muscle positioning technique (IRMPT) for strabismus repair in thyroid eye disease (TED) results in durable relief of diplopia...
Read MoreLower dose of teprotumumab may be effective in active TED with less adverse events
Sensorineural hearing loss has been associated with the use of teprotumumab in patients with thyroid eye disease (TED). A recent...
Read MoreTeprotumumab significantly reduces extraocular muscle cross-sectional area in TED
After treatment with teprotumumab in patients with thyroid eye disease (TED), extraocular muscle (EOM) cross-sectional areas (CSA) is significantly reduced,...
Read MoreMachine-learning model may help in treatment decision-making in TED
A machine-learning model was able to predict the responsiveness to steroid treatment in patients with thyroid eye disease (TED) with...
Read MorePsychosocial impact of TED linked to several socioeconomic risk factors
Patients with thyroid eye disease (TED) are more likely to develop depression and anxiety compared with controls, according to a...
Read MoreSmoking linked with increased risk of surgical intervention for TED
Data from the IRIS Registry has determined that smoking is associated with an increased risk of surgical intervention for thyroid...
Read MoreTocilizumab explored as second-line therapy in steroid-resistant pediatric TED
Tocilizumab as second-line therapy was found to be an effective tool in the management of steroid-resistant thyroid eye disease (TED)...
Read MoreEndocrinologists, ophthalmologists’ roles highlighted in TED consensus statement
The role of endocrinologists in the diagnosis, management, and referral of patients with thyroid eye disease (TED) was assessed in...
Read MoreTeprotumumab treatment effect may be due to IGF-1 signaling disruption
New study data presented at AAO 2022 reveals a specific molecular signature for acute and chronic thyroid eye disease. During...
Read MoreHalf dose of teprotumumab shows potential in active moderate-to-severe TED
In a poster presented at AAO 2022, researchers highlighted the first reported successful treatment of active moderate-to-severe thyroid eye disease...
Read MoreGood outcomes seen after partial teprotumumab treatment
Patients with thyroid eye disease (TED) who received fewer than the standard 8-dose regimen of teprotumumab achieve a significant reduction...
Read MorePotential benefit of teprotumumab dose reduction to be discussed at AAO 2022
Adverse events, particularly hearing loss, in patients with thyroid eye disease (TED) treated with teprotumumab have been documented. In a...
Read More
Contact Info
